Bristol-Myers Squibb

Icon’s Firecrest training recognized by TransCelerate BioPharma

Monday, April 14, 2014 10:13 AM

Icon,a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, has announced that its Firecrest training meets TransCelerate BioPharma’s minimum criteria for International Conference on Harmonization Good Clinical Practice (ICH/GCP) training.

More... »


European researchers to submit proposals focused on curing virological diseases

Tuesday, April 8, 2014 02:41 PM

In a quest to cure chronic virological diseases such as HIV, hepatitis B and hepatitis C, Bristol-Myers Squibb has asked European researchers—notably junior faculty and young investigators—to submit innovative research ideas  to accelerate novel solutions as part of its Partnering for Cure program.

More... »


Five Prime Therapeutics, Bristol-Myers Squibb collaborate

Monday, March 17, 2014 01:37 PM

Five Prime Therapeutics, a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, and Bristol-Myers Squibb (BMS) have signed a collaboration agreement for the discovery, development and commercialization of immuno-oncology therapies directed toward targets identified in two undisclosed immune checkpoint pathways using Five Prime’s proprietary target discovery platform.

More... »

Report: pharmacovigilance market, service providers to reach $5B globally in 2019

Friday, February 28, 2014 12:02 PM

According to a new market report published by Transparency Market Research, the global pharmacovigilance market was valued at $2,147.3 million in 2012 and is estimated to reach a market worth $5,008.2 million in 2019, at a CAGR of 12.9% from 2013 to 2019.

More... »

Inovio Pharmaceuticals expands senior management team

Friday, February 21, 2014 02:38 PM

Inovio Pharmaceuticals has expanded its senior management team with two appointments to help advance the company's growing pipeline of preclinical and clinical DNA vaccines. Inovio has appointed Dr. Laurent Humeau as vice president of R&D and Dr. Jan Marie-Albert Van Tornout as vice president of Clinical Development.

More... »

Spark Therapeutics appoints Elliott Sigal to board of directors

Friday, February 14, 2014 01:27 PM

Spark Therapeutics, a late-stage company developing gene-based medicines for a wide range of debilitating diseases, has appointed Elliott Sigal, M.D., Ph.D., former director, executive vice president and chief scientific officer of Bristol-Myers Squibb, to its board of directors. Elliott led Bristol-Myers Squibb during its ascent as a biopharmaceutical leader and built one of the industry's most productive R&D organizations through his forward-thinking approach to innovation.

More... »

Innate Pharma acquires ANTI-NKG2A from Novo Nordisk

Monday, February 10, 2014 10:19 AM

Innate Pharma has acquired full development and commercialization rights to the anti-NKG2A antibody, a first-in-class immune checkpoint inhibitor ready for phase II development in oncology from global healthcare company Novo Nordisk.

More... »

Report: Absence of 2014 blockbuster drug launches puts R&D productivity at risk

Monday, February 10, 2014 09:54 AM

The past two years have brought a surge of R&D productivity, driving investor confidence and increasing market performance, but 2014 looks to tell a different tale according to a new report from EP Vantage, a source of life science market intelligence and analysis.

More... »

NIH, industry and nonprofits join forces to speed validation of disease targets

Wednesday, February 5, 2014 01:02 PM

The National Institutes of Health, 10 biopharmaceutical companies and several nonprofit organizations have launched an unprecedented partnership to transform the current model for identifying and validating the most promising biological targets of disease for new diagnostics and drug development.

More... »

Bristol-Myers Squibb completes sale of global diabetes business to AstraZeneca

Monday, February 3, 2014 08:51 AM

Bristol-Myers Squibb has completed the previously announced sale of its global diabetes business to AstraZeneca.

More... »


CWWeekly

February 23

Venture capital investors funding novel drug R&D three times more than companies repurposing, improving existing drugs

In appreciation: Karen Woodin will be remembered for her teaching, writing and lasting friendships

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

February

Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

January

All eyes on EMA’s adaptive licensing pilot
Sponsors could offer innovative drugs to patients 8 years sooner

Ice Bucket Challenge a boon for ALS research
Donations soar, but phenomenon difficult to replicate

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs